| Prev Close | 31.52 |
| Open | 31.91 |
| Day Low/High | 31.59 / 31.91 |
| 52 Wk Low/High | 26.03 / 44.18 |
| Volume | 2.94M |
| Avg Volume | 4.24M |
Mylan NV (MYL)
31.84
0.32
1.02
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 515.63M |
| Market Cap | 16.11B |
| EPS | 1.30 |
| P/E Ratio | 30.05 |
| Div & Yield | N.A. (N.A) |
Latest News
4 Scenarios That Will Impact the Market: Market Recon
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.
3 Small Biotech Stocks to Watch in the Fourth Quarter
These are just a few of the names I expect to do well to close out 2018.
3 Small Biotechs on My Q4 Watch List
These are a few of the names I expect to do well to close out 2018.
Tesla Is Not Worth $420, No Matter What Musk Says: Market Recon
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
How to Play Trump's New 'War' With Iran: Market Recon
While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.
Subscriber Comment of the Day (Part Deux)
Subscriber Comment of the Day (Part Deux): Neil S Allergan's stock is probably seeing additional weakness from two announcements: Mylan's biosmilar Botox partnership with Revance and the Food and Drug Administration's extension of the PDUFA date for...
Are Politics and Proxy Firms Killing Your Investment Returns?
Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.
Generic-Drug Stocks Are Looking Sickly
I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.
Staying Liquid
I missed very little and was better served at my "liquid" lunch meeting. Bitcoin was being bitcoin (+17%) with prices contrasting wildly by Exchanges -- a signpost that volatility will be with this commodity for some time. I have a double dose of Bo...
Mid-Afternoon Observations
Some mid afternoon observations: * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...
Here's What's Up This A.M.
The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower. Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside. Co...
How to Trade the Saudi Arabia Anti-Corruption Moves: Market Recon
The Saudi Arabian economy needs to rebalance away from oil.
Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers
The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.
Mylan Takes a Hit on Price Collusion Probe
Yesterday I reemphasized that Teva should be avoided. Today Mylan was hit by an apparent extension of a generic drug pricing collusion probe. Mylan's shares have fallen by nearly seven precnet in the morning session.
Here's Why Teva Isn't My Cup of Tea
On Wednesday I explained why I would avoid Teva Pharmaceutical Industries : I know by the Comments Section that there has been a lot of bottom fishing in Teva (TEVA) . I had done a few hours of research on the company over the last months and passed...
Records for Wall Street, While FDA Approval Pushes Mylan to Top S&P 500
The three major indexes closed at record highs, the Dow for its third day in a row, the Nasdaq its fourth, and the S&P 500 its fifth.
Only the Brave Trade Mylan
Risk is harder to gauge than a price target after a gap like the one we have on MYL.
Teva Still Hurts From Self-Inflicted Wounds
It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.
Video: Jim Cramer on Netflix, Pepsi, Ford, Tesla, Mylan and Costco
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks.
Jim Cramer Reacts to Mylan's Multiple Sclerosis Drug
Mylan scored FDA approval for a generic version of Teva Pharmaceuticals' multiple sclerosis drug, Copaxone.
Teva Still Hurts From Self-Inflicted Wounds
It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.
A Look Back At Teva's History As Mylan Delivers the Drug-Maker Another Blow
The Israeli pharma company Teva has established a rich history since its founding in 1901. Can it continue to survive as it faces one challenge after another?
Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers
The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.
Mylan's Copycat Drug OK Likely to Ding Allergan Shares
Mylan's drug approval announced this morning is a big negative for Teva Pharmaceutical Industries and likely will result in a $3 to $5 drop in Allergan's shares in the early going.
Will Allergan's Deal With Tribe Hold Up?
Answering questions from the biotech mailbag.
